Breaking Finance News

AstraZeneca plc (ADR) (NYSE:AZN) has been downgraded to Sell in a statement by Zacks Investment Research today.

Yesterday AstraZeneca plc (ADR) (NYSE:AZN) traded -1.30% lower at $32.65. The company’s 50-day moving average is $33.36 and its 200-day moving average is $30.71. With the last stock price close up 6.07% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 2,730,237 shares of AZN changing hands under the typical 5,968,140

Zacks Investment Research has downgraded AstraZeneca plc (ADR) (NYSE:AZN) to Sell in a statement released on 10/04/2016.

Performance Chart

AstraZeneca plc (ADR) (NYSE:AZN)

With a total market value of $0, AstraZeneca plc (ADR) has price-earnings ratio of 37.22 with a 52 week low of $26.97 and a 52 week high of $35.04 .

In addition to Zacks Investment Research reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $35.41 with one analyst rating the company a strong buy, zero analysts rating the company a buy, three analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

Brief Synopsis About AstraZeneca plc (ADR) (NYSE:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.